The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy

Victoria Serhiyenko; Marta Hotsko; Alexandr Serhiyenko; Oksana Snitynska; Ludmila Serhiyenko; Volodymyr Segin

doi:doi:10.11648/j.ajim.20200805.11

| Peer-Reviewed

The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy

Victoria Serhiyenko, Marta Hotsko, Alexandr Serhiyenko, Oksana Snitynska, Ludmila Serhiyenko, Volodymyr Segin

Published in American Journal of Internal Medicine (Volume 8, Issue 5)

Received: 7 July 2020 Accepted: 22 July 2020 Published: 13 August 2020

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Development of chronic complications in type 2 diabetes mellitus (T2DM), namely cardiac automonic neuropathy (CAN), had been implicated as an independent risk factor for cardiovascular mortality. This paper presents the results obtained during the study of possible alpha-lipoic acid (ALA) impact on the state of insulin resistance (IR), the content of some pro- and anti-inflammatory factors in patients with T2DM and definite stage of CAN. Our study involved 33 persons with diagnosed T2DM and definite CAN, which were allocated to one of two groups. The control group (15 patients) received standard hypoglycemic treatment, whereas the intervention group (18 patients) received ALA 600 mg in film-coated tablets/q.d. in addition to standard therapy. Treatment period was 3 months in duration. Levels of glycated hemoglobin A1c, glucose, immunoreactive insulin (IRI), leptin, interleukin (IL) IL-6 and IL-8, high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha) in the blood were measured. TNF-alpha/IL-10 ratio and Homeostasis model assessment IR (HOMA-IR) were calculated. The significant reduction in glucose, IRI, leptin concentration and HOMA-IR parameters; decrease in the pro-inflammatory link activity, namely hs-CRP, TNF-alpha, IL-6 and IL-8 levels, TNF-alpha/IL-10 ratio, with no changes in IL-10 content after 3 months of treatment was found. The results of our study demonstrated the decrease in the pro-inflammatory link activity after treatment and allow us to consider ALA as one of the promising drug for complex treatment of definite stage of CAN in patients with T2DM.

Published in	American Journal of Internal Medicine (Volume 8, Issue 5)
DOI	10.11648/j.ajim.20200805.11
Page(s)	197-203
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

Diabetic Cardiac Autonomic Neuropathy, Alpha-Lipoic Acid, Inflammation, Type 2 Diabetes Mellitus

References

[1]	Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R et al. Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011; 27 (7): 639-653. doi: 10.1002/dmrr.1239.
[2]	Spallone V. Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet. Diabetes Metab. J. 2019; 43 (1): 3-30. doi: 10.4093/dmj.2018.0259.
[3]	Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care. 2017; 40: 136-154. doi: 10.2337/dc16-2042.
[4]	Ziegler D, Keller J, Maier C, Pannek J. Diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2014; 122: 406-415. doi: 10.1055/s-0034-1366435.
[5]	Tesfaye S, Boulton AJ, Dyck PJ Freeman R, Horowitz M, Kempler P et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010; 33 (10): 2285-2293. doi: 10.2337/dc10-1303.
[6]	Serhiyenko VA, Serhiyenko AA. Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives? World J Diabetes. 2015; 6 (2): 245-258. doi: 10.4239/wjd.v6.i2.245.
[7]	Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 2018; 9 (1): 1-24. doi: 10.4239/wjd.v9.i1.1.
[8]	Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care. 1999; 20 (2): 369-373. doi: 10.2337/diacare.20.3.369.
[9]	Lee SJ, Jeong SJ, Lee YC, Lee YH., Lee JE., Kim CH et al. Effects of high-dose α-lipoic acid on heart rate variability of type 2 diabetes mellitus patients with cardiac autonomic neuropathy in Korea. Diabetes Metab J. 2017; 41 (4): 275-283. Doi: 10.4093/dmj.2017.41.4.275.
[10]	Gomes MB, Negrato CA. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr. 2014; 6 (1): 80. doi: 10.1186/1758-5996-6-80.
[11]	Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985; 8 (5): 491-498. doi: 10.2337/diacare.8.5.491.
[12]	Spallone V, Bellarvere F, Scionti L, Maule S, Quadri R, Bax G et al. Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovascular Dis. 2011; 21 (1): 69-78. doi: 10.1002/dmrr.1239
[13]	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia.1985; 28 (7): 412-419. doi: 10.1007/BF00280883.
[14]	Rochette L, Ghibu S, Muresan A, Vergely C. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol. 2015; 93 (12): 1021-1027. doi: 10.1139/cjpp-2014-0353.
[15]	Ahmadvand H, Jamor P. Effects of alpha lipoic acid on level of NO and MPO activity in diabetic rats. Ann Res Antioxid. 2017; 2: e04. http://annresantioxidants.com. Accessed 04 Jun 2017.
[16]	Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud. 2009; 6 (4): 230-236. doi: 10.1900/RDS.2009.6.230.
[17]	Suh JH, Wang H, Liu RM, Hagen TM. (R)-alpha-lipoic acid reverses the agerelated loss in GSH redox status in post-mitotic tissues: evidence for increased cysteine requirement for GSH synthesis. Arch Biochem Biophys. 2004; 423 (1): 126-135. doi: 10.1016/j.abb.2003.12.020.
[18]	Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic acid. Front Pharmacol. 2011; 2: 69. doi: 10.3389/fphar.2011.00069.
[19]	Dinicola S, Proietti S, Cucina A, Bizzarri M, Fuso A. Alpha-lipoic acid downregulates IL-1β and IL-6 by DNA hypermethylation in SK-N-BE neuroblastoma cells. Antioxidants (Basel). 2017; 6 (4): E74. doi: 10.3390/antiox6040074.
[20]	Shay K, Hagen TM. Age-associated impairment of Akt phosphorylation in primary rat hepatocytes is remediated by alpha-lipoic acid through PI3 kinase, PTEN, and PP2A. Biogerontology. 2009; 10 (4): 443-456. doi: 10.1007/s10522-008-9187-x.
[21]	Packer L, Cadenas E. Lipoic acid: energy metabolism and redox regulation of transcription and cell signalling. J Clin Biochem Nutr. 2011; 48 (1): 26-32. doi: 10.3164/jcbn.11-005FR.
[22]	Koriyama Y, Nakayama Y, Matsugo S, Kato S. Protective effect of lipoic acid against oxidative stress is mediated by Keap1/Nrf2-dependent heme oxygenase-1 induction in the RGC-5 cellline. Brain Res. 2013; 1499: 145-157. doi: 10.1016/j.brainres.2012.12.041.
[23]	Park S, Karunakaran U, Jeoumg NH, Jeon JH, Lee IK. Physiological effect and therapeutic application of alpha lipoic acid. Curr Med Chem. 2014; 21 (32): 3636-3645. doi: 10.2174/0929867321666140706141806.
[24]	Hiller S, DeKroon R, Hamlett ED, Xu L, Osorio C, Robinette J et al. Alpha-lipoic acid supplementation protects enzymes from damage by nitrosative and oxidative stress. Biochim Biophys Acta. 2016; 1860 (1): 36-45. Doi: 10.1016/j.bbagen.2015.09.001.
[25]	Serhiyenko V, Serhiyenko L, Suslik G, Serhiyenko A. Alpha-lipoic acid: mechanisms of action and beneficial effects in the prevention and treatment of diabetic complications. MOJ Public Health. 2018; 7 (4): 174-178. doi: 10.15406/mojph.2018.07.00224.
[26]	Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009; 1790 (10): 1149-1160. doi: 10.1016/j.bbagen.2009.07.026.
[27]	Ibrahimpasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. Med Arch. 2013; 67 (1): 7-9. doi: 10.5455/medarh.2013.67.7-9.
[28]	Morakinyo AO, Awobajo FO, Adegoke OA. Effects of alpha lipoic acid on blood lipids, renal indices, antioxidant enzymes, insulin and glucose level in streptozotocin-diabetic rats. Biol Med. 2013; 5: 26-33. http://www.biolmedonline.com. Accessed 20 Feb 2013.
[29]	Feng B, Yan XF, Xue JL, Xu L, Wang H. The protective effects of α-lipoic acid on kidneys in type 2 diabetic Goto-Kakisaki rats via reducing oxidative stress. Int J Mol Sci. 2013; 14 (4): 6746-6756. doi: 10.3390/ijms14046746.
[30]	Pitocco D, Tesauro M, Alessandro R, Ghirlanda G, Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci. 2013; 14 (11): 21525-21550. doi: 10.3390/ijms141121525.
[31]	Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005; 111 (3): 343-348. doi: 10.1161/01.CIR.0000153272.48711.B9.
[32]	Serhiyenko V, Serhiyenko L, Krasnyi M, Serhiyenko A. Alpha-lipoic acid: therapeutic potential in diabetic neuropathies. Curre Res Diabetes Obes J. 2018; 7 (3): 555713. doi: 10.19080/CRDOJ.2018.07.555713.

Cite This Article

Plain Text BibTeX RIS

APA Style

Victoria Serhiyenko, Marta Hotsko, Alexandr Serhiyenko, Oksana Snitynska, Ludmila Serhiyenko, et al. (2020). The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy. American Journal of Internal Medicine, 8(5), 197-203. https://doi.org/10.11648/j.ajim.20200805.11

Copy | Download

ACS Style

Victoria Serhiyenko; Marta Hotsko; Alexandr Serhiyenko; Oksana Snitynska; Ludmila Serhiyenko, et al. The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy. Am. J. Intern. Med. 2020, 8(5), 197-203. doi: 10.11648/j.ajim.20200805.11

Copy | Download

AMA Style

Victoria Serhiyenko, Marta Hotsko, Alexandr Serhiyenko, Oksana Snitynska, Ludmila Serhiyenko, et al. The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy. Am J Intern Med. 2020;8(5):197-203. doi: 10.11648/j.ajim.20200805.11

Copy | Download

@article{10.11648/j.ajim.20200805.11,
  author = {Victoria Serhiyenko and Marta Hotsko and Alexandr Serhiyenko and Oksana Snitynska and Ludmila Serhiyenko and Volodymyr Segin},
  title = {The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy},
  journal = {American Journal of Internal Medicine},
  volume = {8},
  number = {5},
  pages = {197-203},
  doi = {10.11648/j.ajim.20200805.11},
  url = {https://doi.org/10.11648/j.ajim.20200805.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20200805.11},
  abstract = {Development of chronic complications in type 2 diabetes mellitus (T2DM), namely cardiac automonic neuropathy (CAN), had been implicated as an independent risk factor for cardiovascular mortality. This paper presents the results obtained during the study of possible alpha-lipoic acid (ALA) impact on the state of insulin resistance (IR), the content of some pro- and anti-inflammatory factors in patients with T2DM and definite stage of CAN. Our study involved 33 persons with diagnosed T2DM and definite CAN, which were allocated to one of two groups. The control group (15 patients) received standard hypoglycemic treatment, whereas the intervention group (18 patients) received ALA 600 mg in film-coated tablets/q.d. in addition to standard therapy. Treatment period was 3 months in duration. Levels of glycated hemoglobin A1c, glucose, immunoreactive insulin (IRI), leptin, interleukin (IL) IL-6 and IL-8, high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha) in the blood were measured. TNF-alpha/IL-10 ratio and Homeostasis model assessment IR (HOMA-IR) were calculated. The significant reduction in glucose, IRI, leptin concentration and HOMA-IR parameters; decrease in the pro-inflammatory link activity, namely hs-CRP, TNF-alpha, IL-6 and IL-8 levels, TNF-alpha/IL-10 ratio, with no changes in IL-10 content after 3 months of treatment was found. The results of our study demonstrated the decrease in the pro-inflammatory link activity after treatment and allow us to consider ALA as one of the promising drug for complex treatment of definite stage of CAN in patients with T2DM.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy
AU  - Victoria Serhiyenko
AU  - Marta Hotsko
AU  - Alexandr Serhiyenko
AU  - Oksana Snitynska
AU  - Ludmila Serhiyenko
AU  - Volodymyr Segin
Y1  - 2020/08/13
PY  - 2020
N1  - https://doi.org/10.11648/j.ajim.20200805.11
DO  - 10.11648/j.ajim.20200805.11
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 197
EP  - 203
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20200805.11
AB  - Development of chronic complications in type 2 diabetes mellitus (T2DM), namely cardiac automonic neuropathy (CAN), had been implicated as an independent risk factor for cardiovascular mortality. This paper presents the results obtained during the study of possible alpha-lipoic acid (ALA) impact on the state of insulin resistance (IR), the content of some pro- and anti-inflammatory factors in patients with T2DM and definite stage of CAN. Our study involved 33 persons with diagnosed T2DM and definite CAN, which were allocated to one of two groups. The control group (15 patients) received standard hypoglycemic treatment, whereas the intervention group (18 patients) received ALA 600 mg in film-coated tablets/q.d. in addition to standard therapy. Treatment period was 3 months in duration. Levels of glycated hemoglobin A1c, glucose, immunoreactive insulin (IRI), leptin, interleukin (IL) IL-6 and IL-8, high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha) in the blood were measured. TNF-alpha/IL-10 ratio and Homeostasis model assessment IR (HOMA-IR) were calculated. The significant reduction in glucose, IRI, leptin concentration and HOMA-IR parameters; decrease in the pro-inflammatory link activity, namely hs-CRP, TNF-alpha, IL-6 and IL-8 levels, TNF-alpha/IL-10 ratio, with no changes in IL-10 content after 3 months of treatment was found. The results of our study demonstrated the decrease in the pro-inflammatory link activity after treatment and allow us to consider ALA as one of the promising drug for complex treatment of definite stage of CAN in patients with T2DM.
VL  - 8
IS  - 5
ER  -

Copy | Download

Author Information

Victoria Serhiyenko

Department of Endocrinology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Marta Hotsko

Department of Endocrinology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Alexandr Serhiyenko

Department of Endocrinology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Oksana Snitynska

Department of Endocrinology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Ludmila Serhiyenko

Department of Medical Biology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Volodymyr Segin

Lviv Regional State Clinical Treatment and Diagnostic Endocrinology Center, Lviv, Ukraine

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Victoria Serhiyenko, Marta Hotsko, Alexandr Serhiyenko, Oksana Snitynska, Ludmila Serhiyenko, et al. (2020). The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy. American Journal of Internal Medicine, 8(5), 197-203. https://doi.org/10.11648/j.ajim.20200805.11

Copy | Download

ACS Style

Victoria Serhiyenko; Marta Hotsko; Alexandr Serhiyenko; Oksana Snitynska; Ludmila Serhiyenko, et al. The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy. Am. J. Intern. Med. 2020, 8(5), 197-203. doi: 10.11648/j.ajim.20200805.11

Copy | Download

AMA Style

Victoria Serhiyenko, Marta Hotsko, Alexandr Serhiyenko, Oksana Snitynska, Ludmila Serhiyenko, et al. The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy. Am J Intern Med. 2020;8(5):197-203. doi: 10.11648/j.ajim.20200805.11

Copy | Download

@article{10.11648/j.ajim.20200805.11,
  author = {Victoria Serhiyenko and Marta Hotsko and Alexandr Serhiyenko and Oksana Snitynska and Ludmila Serhiyenko and Volodymyr Segin},
  title = {The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy},
  journal = {American Journal of Internal Medicine},
  volume = {8},
  number = {5},
  pages = {197-203},
  doi = {10.11648/j.ajim.20200805.11},
  url = {https://doi.org/10.11648/j.ajim.20200805.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20200805.11},
  abstract = {Development of chronic complications in type 2 diabetes mellitus (T2DM), namely cardiac automonic neuropathy (CAN), had been implicated as an independent risk factor for cardiovascular mortality. This paper presents the results obtained during the study of possible alpha-lipoic acid (ALA) impact on the state of insulin resistance (IR), the content of some pro- and anti-inflammatory factors in patients with T2DM and definite stage of CAN. Our study involved 33 persons with diagnosed T2DM and definite CAN, which were allocated to one of two groups. The control group (15 patients) received standard hypoglycemic treatment, whereas the intervention group (18 patients) received ALA 600 mg in film-coated tablets/q.d. in addition to standard therapy. Treatment period was 3 months in duration. Levels of glycated hemoglobin A1c, glucose, immunoreactive insulin (IRI), leptin, interleukin (IL) IL-6 and IL-8, high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha) in the blood were measured. TNF-alpha/IL-10 ratio and Homeostasis model assessment IR (HOMA-IR) were calculated. The significant reduction in glucose, IRI, leptin concentration and HOMA-IR parameters; decrease in the pro-inflammatory link activity, namely hs-CRP, TNF-alpha, IL-6 and IL-8 levels, TNF-alpha/IL-10 ratio, with no changes in IL-10 content after 3 months of treatment was found. The results of our study demonstrated the decrease in the pro-inflammatory link activity after treatment and allow us to consider ALA as one of the promising drug for complex treatment of definite stage of CAN in patients with T2DM.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy
AU  - Victoria Serhiyenko
AU  - Marta Hotsko
AU  - Alexandr Serhiyenko
AU  - Oksana Snitynska
AU  - Ludmila Serhiyenko
AU  - Volodymyr Segin
Y1  - 2020/08/13
PY  - 2020
N1  - https://doi.org/10.11648/j.ajim.20200805.11
DO  - 10.11648/j.ajim.20200805.11
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 197
EP  - 203
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20200805.11
AB  - Development of chronic complications in type 2 diabetes mellitus (T2DM), namely cardiac automonic neuropathy (CAN), had been implicated as an independent risk factor for cardiovascular mortality. This paper presents the results obtained during the study of possible alpha-lipoic acid (ALA) impact on the state of insulin resistance (IR), the content of some pro- and anti-inflammatory factors in patients with T2DM and definite stage of CAN. Our study involved 33 persons with diagnosed T2DM and definite CAN, which were allocated to one of two groups. The control group (15 patients) received standard hypoglycemic treatment, whereas the intervention group (18 patients) received ALA 600 mg in film-coated tablets/q.d. in addition to standard therapy. Treatment period was 3 months in duration. Levels of glycated hemoglobin A1c, glucose, immunoreactive insulin (IRI), leptin, interleukin (IL) IL-6 and IL-8, high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha) in the blood were measured. TNF-alpha/IL-10 ratio and Homeostasis model assessment IR (HOMA-IR) were calculated. The significant reduction in glucose, IRI, leptin concentration and HOMA-IR parameters; decrease in the pro-inflammatory link activity, namely hs-CRP, TNF-alpha, IL-6 and IL-8 levels, TNF-alpha/IL-10 ratio, with no changes in IL-10 content after 3 months of treatment was found. The results of our study demonstrated the decrease in the pro-inflammatory link activity after treatment and allow us to consider ALA as one of the promising drug for complex treatment of definite stage of CAN in patients with T2DM.
VL  - 8
IS  - 5
ER  -

Copy | Download